TargED Biopharmaceuticals develops TGD001, a targeted thrombolytic therapy utilizing small antibodies for localized enzyme delivery to effectively treat various forms of thrombosis. This approach aims to enhance thrombolysis in patients suffering from conditions such as Immune Thrombotic Thrombocytopenic Purpura and Acute Ischemic Stroke, addressing a significant global health issue that contributes to over 16 million deaths annually.
Funding
$44.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
APSLFounders
Product
Problem
Thrombosis, a leading cause of death worldwide, requires effective thrombolytic therapies that can address various forms of blood clots regardless of their composition. Current treatments may not always be effective or timely in dissolving clots, leading to significant morbidity and mortality.
Solution
TargED Biopharmaceuticals is developing TGD001, a first-in-class biological drug that utilizes small antibodies (VHH) for targeted enzyme delivery to sites of thrombosis. This approach enables localized thrombolysis, aiming to improve the breakdown of blood clots in patients with various thrombotic disorders. TGD001 is preclinically validated for Immune Thrombotic Thrombocytopenic Purpura (iTTP) and Acute Ischemic Stroke (AIS), with the goal of accelerating thrombolysis irrespective of the thrombus composition.
Target Audience
The primary target audience includes patients suffering from thrombotic disorders such as Immune Thrombotic Thrombocytopenic Purpura (iTTP) and Acute Ischemic Stroke (AIS).
Features
- Utilizes small antibodies (VHH) for targeted delivery of thrombolytic enzymes.
- Designed to address various forms of thrombosis, including iTTP and AIS.
- Preclinically validated to demonstrate effective thrombolysis.
- Aims to accelerate the breakdown of blood clots, regardless of their composition.